Example: Heart Attack

Clinical Trials Sponsored by Teva Pharmaceutical Industries

Total 405 results

NCT02215941

Completed

Study to Characterize the Pharmacokinetics and Safety of TV-45070 Ointment in Healthy Volunteers

Conditions: Pharmacokinetics
NCT02085863

Completed

A Phase I Study in Young Healthy Women to Investigate the Effects of Laquinimod on Standard Oral Contraceptive When Both Treatments Are Given Together

Conditions: Pharmacokinetics; Pharmacodynamics
NCT02025556

Completed

A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine

Conditions: Episodic Migraine Headache
NCT02021773

Completed

Assessment of LBR-101 In Chronic Migraine

Conditions: Chronic Migraine
NCT01991509

Completed

Safety and Bioavailability of IV and SC LBR-101

Conditions: Bioavailability and Pharmacokinetics
NCT01990443

Completed

Absolute Bioavailability of Reslizumab in Healthy Subjects

Conditions: Absolute Bioavailability
NCT01975298

Withdrawn

A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Conditions: Relapsing Remitting Multiple Sclerosis
NCT01940601

Withdrawn

Pharmacodynamics, Pharmacokinetics, Efficacy and Safety of Balugrastim in Pediatric Patients With Solid Tumors

Conditions: Solid Tumors
NCT01903824

Completed

Pharmacokinetics and Pharmacodynamics (PK/PD) of CEP-26401 in Healthy Subjects

Conditions: Cognitive Impairment
NCT01887366

Completed

Efficacy and Safety of TV-1380 as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects

Conditions: Cocaine Addiction
NCT01879748

Completed

A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Rasagiline

Conditions: Parkinson's Disease
NCT01874145

Completed

Safety and Tolerability of Glatiramer Acetate

Conditions: Relapsing-Remitting Multiple Sclerosis
NCT01857323

Completed

Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)

Conditions: Asthma; Chronic Obstructive Pulmonary Disease (COPD)
NCT01844869

Completed

An Open-Label Study to Investigate the Pharmacokinetics of Omacetaxine Mepesuccinate

Conditions: Hematologic Malignancies; Solid Tumors
NCT01844401

Completed

Pharmacokinetic and Pharmacodynamic Profiles of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients With Asthma

Conditions: Asthma
NCT01803555

Completed

Efficacy and Safety Evaluation of Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®

Conditions: Asthma
NCT01795859

Completed

First Time Use of SD-809 in Huntington Disease

Conditions: Chorea
NCT01791972

Completed

Efficacy of Albuterol SPIROMAX® in Adult and Adolescent Patients With Exercise-Induced Bronchoconstriction (EIB)

Conditions: Exercise-Induced Bronchoconstriction (EIB)
NCT01785433

Completed

To Compare the Pharmacokinetics of Tiotropium in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Conditions: COPD
NCT01783548

Completed

Study of an Investigational Nasal Aerosol or Placebo in Children (Ages 4 to 11) With Perennial Allergic Rhinitis (PAR)

Conditions: Allergic Rhinitis
NCT01769677

Completed

A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet

Conditions: Pain
NCT01758978

Completed

A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet

Conditions: Pain
NCT01698320

Completed

Safety Study of Albuterol Spiromax® in Subjects With Asthma

Conditions: Asthma
NCT01697956

Completed

Hypothalamic-Pituitary-Adrenal (HPA)-Axis Study in Pediatric Subjects With Perennial Allergic Rhinitis (PAR)

Conditions: Allergic Rhinitis
NCT01632540

Completed

Effectiveness of Beclomethasone Dipropionate Nasal Aerosol for Perennial Allergic Rhinitis

Conditions: Perennial Allergic Rhinitis (PAR)